ANVS Annovis Bio, Inc.
$0.98▲ +2.41%
Healthcare
Other
Volume 326.1K
Avg Volume (10D) 615.7K
Key Metrics & Fundamentals
Market Cap
$41.83M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.93 - 5.50
% vs 50 MA
-27.40%
% vs 200 MA
-51.22%
RSI-14
32.1
MACD Histogram
+0.0000
Beta (1Y vs SPY)
1.53
Free Cash Flow
-$21.91M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$15.36M
COGS
–
Operating Exp
$14.38M
Operating Income
-$14.38M
EBIT
-$14.38M
Pretax Income
-$14.82M
Net Income
-$14.82M
EPS (Diluted)
-0.40
Price & Volume History
Loading chart…
Recent News
Annovis to Attend the CTAD 2026 with Three Presentations
GlobeNewswire · Oct 22, 2026 8:00 AM ET
Parkinson's Disease Market Poised for Expansion During the Forecast Period (2026-2036) Amid JUVMO Approval and Emerging Therapeutic Innovations | DelveInsight
PR Newswire · Oct 6, 2026 10:31 AM ET
Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer’s Disease
GlobeNewswire · Sep 23, 2026 8:00 AM ET
Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks · Sep 8, 2026 9:35 AM ET
Annovis Bio Targets March 2027 Alzheimer’s Readout, Prepares Rolling NDA
MarketBeat · Sep 2, 2026 10:01 PM ET
Annovis to Host Corporate Update Webinar on September 2, 2026
GlobeNewswire · Aug 25, 2026 8:00 AM ET
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results
GlobeNewswire · Aug 14, 2026 8:00 AM ET
The Next Billion-Dollar Opportunity in Alzheimer's Disease Market: 6 Pipeline Therapies to Watch | DelveInsight
PR Newswire · Aug 6, 2026 10:31 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See ANVS's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.